Eric K. Rowinsky - Concepedia

Author

Eric K. Rowinsky

The University of Texas Health Science Center at San Antonio ORCID

Also Known As

E K Rowinsky, E ROWINSKY, E Rowinsky, E. K. Rowinsky, E. Rowinsky, E.K Rowinsky, E.K. Rowinsky, ERIC K. ROWINSKY, Eric K Rowinsky, Eric K. Rowinsky

477

Publications

41.1K

Citations

H-Index

155

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio Johns Hopkins University Brooke Army Medical Center The University of Texas MD Anderson Cancer Center

About

Eric K. Rowinsky is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	125	10.4K
2	Health Sciences	12	13	1.2K
3	Natural Sciences	8	8	545
4	Engineering	2	2	22
5	Public Health	1	1	395

Eric K. Rowinsky

257

Publications

32.4K

Citations

H-Index

Page 1

	Year	Citations
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck James A. Bonner, Paul M. Harari, J. Giralt, New England Journal of Medicine	2006	5.1K
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival James A. Bonner, Paul M. Harari, J. Giralt, The Lancet Oncology Advanced HeadNeck CancerRadiation TherapyMedicineRandomised Trial	2009	2K
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond, Journal of Clinical Oncology	2004	1.1K
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Mark J. Ratain, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2006	1K
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Journal of Clinical Oncology	2001	997
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial Malcolm Ranson, Lisa A. Hammond, D. K. Ferry, Journal of Clinical Oncology	2002	762
Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) George W. Sledge, Donna Neuberg, Patricia Bernardo, Journal of Clinical Oncology	2003	701
Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial Philip Bonomi, KyungMann Kim, Diane L. Fairclough, Journal of Clinical Oncology	2000	594
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G<sub>1</sub> Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens, Journal of Clinical Oncology	2010	551
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford, Journal of Clinical Oncology	2006	536

Page 1